Cargando…
Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule
The standard first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma combines Cisplatin, 5 Fluorouracil and Cetuximab, but many patients aren’t eligible. We retrospectively evaluated the efficacy and the tolerability of Carboplatin and Paclitaxel in this indication, mostly...
Autores principales: | Pêtre, Adeline, Dalban, Cécile, Karabajakian, Andy, Neidhardt, Eve-Marie, Roux, Pierre Eric, Poupart, Marc, Deneuve, Sophie, Zrounba, Philippe, Fayette, Jérome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955142/ https://www.ncbi.nlm.nih.gov/pubmed/29774120 http://dx.doi.org/10.18632/oncotarget.25157 |
Ejemplares similares
-
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients
por: Fayette, Jérôme, et al.
Publicado: (2016) -
Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief
por: Karabajakian, Andy, et al.
Publicado: (2018) -
Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015) -
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016) -
Proof of Concept of a Binary Blood Assay for Predicting Radiosensitivity
por: Deneuve, Sophie, et al.
Publicado: (2021)